CNS

Pheno Therapeutics has entered an agreement with UCB for the rights to develop, manufacture and commercialise a preclinical-stage programme of novel small molecules designed to promote remyelination.   “Pheno Therapeutics utilised its proprietary human phenotypic screening platform to discover novel and tractable therapeutic targets to modulate oligodendrocyte biology and promote remyelination. This license allows us to […]

PrecisionLife and Ono Pharmaceutical have agreed a multi-target discovery and validation partnership.   The R&D collaboration will leverage PrecisionLife’s combinatorial analytics-generated insights to identify novel therapeutic targets and patient stratification biomarkers in central nervous system (CNS) disorders for development by Ono.  PrecisionLife analyses multi-modal datasets including genomic, clinical, and epidemiological data to accurately stratify patients and […]

Minoryx and Neuraxpharm have agreed a strategic alliance to provide a new therapy for rare CNS disease patients in Europe.  The companies have entered into a license agreement for the European rights to leriglitazone, currently under European Medicines Agency (EMA) review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD).  Minoryx has granted Neuraxpharm exclusive European rights […]

The newest addition to the free DDW podcast is the In Conversation With series, where DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this latest episode, DDW’s Megan Thomas speaks with Dr Mark Varney, the Chief Scientific Officer at PsychoGenics, who discusses […]

A new start-up has launched with an aim of developing therapeutics that address synaptic dysfunction in patients suffering from central nervous system (CNS) disorders.   Gate Neurosciences was founded in 2019 by a team of neuroscientists with the goal of addressing the urgent need for more effective treatments for CNS disorders, and to overcome long-standing challenges […]

Blue Oak Pharmaceuticals, an innovator in the discovery of transformative CNS drugs, and Exscientia, a clinical-stage Artificial Intelligence (AI) drug-discovery company, have announced an innovative drug-discovery collaboration to treat brain disorders. This collaboration combines Blue Oak’s therapeutic area expertise and ability to design novel, CNS focused privileged chemotypes with Exscientia’s proven ability to apply AI […]